Evelia F. Iglesias. M.D

Medical Director

License and Certification:

Medical Doctor (Cuba and USA)
Board Certified Neuropsychiatrist (USA)
Clinical Pathologist (Cuba)

Education and Training:

03/26/2024
NIDA CLINICAL TRIALS NETWORK
Good Clinical Practices. Exp: 03/26/2027

Introduction
Institutional Review Boards
Informed Consent
Confidentiality & Privacy
Participant Safety & Adverse Events
Quality Assurance
The Research Protocol
Documentation & Record Keeping
Research Misconduct
Roles & Responsibilities
Recruitment & Retention
Investigational New Drugs

04/23/2024
Transporting Dangerous Goods Training
Mayo Clinic Laboratories Exp: 23Apr2026

04/23/2024
Handling/ offering for transportation of Dangerous Goods
Mayo Clinic Laboratories (IATA) Exp:23Apr2026

09/1984-08 / 90
Medical Doctor
Institute of Medical Sciences of Havana
Pinar Del Rio faculty, Cuba

07/09-06/2013
NeuroPsychiatrist
Texas Tech University Health and science Center
El Paso Texas

Professional Experience:

02/2024- Present
Principal-investigator
CLA Research Center, Naples, Fl

07/2013 – Present
Psychiatrist/Medical Director at Clinica Los Angeles, Naples, Fl.
Psychiatrist at Miami Counseling and Resource Center, Coral Gables, Fl.

07/2009-06/2013
Resident Physician in Neuropsychiatry
Texas tech University Health and science center
El Paso Texas

11/1996-05/2009
Medical Technologist
DSI Laboratories Community Hospital, Immunology, Blood Bank, Transfusion Services, Naples, FL

11/2001-05/2003
Medical Technologist, Chemistry, Hematology, Microbiology at Anchor Health Centers, Naples, Fl

09/ 1992-05/1995
Medical Doctor Clinical Pathology
Abel Santamarina Hospital.
Pinar Del Rio, Cuba

09/1990-09/1992
Medical Doctor, Clinical Pathology and Biochemistry Research at Superior Institute of Medical Sciences Of Havana Cuba

Volunteer Experience:

09-1993
Collaboration with the CDC of Atlanta Field Team at Abel Santamaria Hospital, Center of operations during the Cuban Epidemic Neuropathy.

Clinical Trials Experience:

A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of XXXX in Adults with Focal Seizures (07/2025-ONGOING)
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of XXXX in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic
Seizures(05/2025-Ongoing)
An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive XXX in Subjects with Inadequately Controlled Symptoms of Schizophrenia.
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Trial to Assess the Efficacy and Safety of XXXX for treatment of Agitation in Subject with Dementia of the Alzheimer’s. (2019-2020).
A Phase III Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Effectiveness of XXX (Human), XXXXXX)for the treatment of Mild to Moderate Alzheimer’s Disease (AD). (2019-2020)
A Multicenter, Double-Blind, Randomized, Placebo-Controller ,4-Armed Parallel Group Study to Evaluate the Efficacy of XXX and XXX in the Treatment on Acute Migraine Headache in Adolescents. (2019-2021).
SKK SI 6603/1131 and 1132.Hernia Red Lumbar Disc Study. (2015- 2016)
Lower Back Pain and Opioid Induced Constipation. Perdue Pharma.(2012-2013)

A research trial on standardization of free Radicals Markers with determination of comparative levels on smokers and non-smokers.
A research trial measuring oxidative stress markers on smokers and non- smokers before and after use of antioxidants.
Personal Research Project presented at 7th annual research colloquium at Texas Tech University, Health Science Centers on Risk Factors for suicidal behavior in Hispanic patients with diagnosis of Bipolar I Disorder.
Genetics of Bipolar and related Disorders
Pre-Clinical trials of standardization of CKBB in serum of rabbits as marker of brain.
1-01/2026 -ongoing –A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Delaying Time to Relapse
Compared with Placebo in Adult Participants with Bipolar Disorder (RENEW-Bipolar-1)
2- 02-2026-ongoing A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the
Efficacy and Safety of Adjunctive Treatment with Brenipatide in Delaying Time to Relapse
Compared with Placebo in Adult Participants with Major Depressive Disorder (RENEWMDD-1)
3-04-2026-ongoing-A Phase 2 Multicenter, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Adult Participants with Schizophrenia (RENEWScz-1)
4-04-2026-ongoing-A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the
Efficacy and Safety of Adjunctive Treatment with Brenipatide in Delaying Time to Relapse
Compared with Placebo in Adult Participants with Major Depressive Disorder (RENEWMDD-2)

Languages:

Fluent English and Spanish